From the publishers of JADPRO

DLBCL Resource Center

Advertisement

Noninvasive minimal residual disease assessment in relapsed/refractory large B-cell lymphoma using digital droplet PCR

Last Updated: Wednesday, March 13, 2024

Researchers investigating a noninvasive digital droplet PCR approach using plasma-derived ctDNA for minimal residual disease assessment in relapsed/refractory DLBCL found that it is feasible, is affordable, and offers fast turnover and that it is highly predictive of outcomes in this disease state. 

European Journal of Haematology
Advertisement
News & Literature Highlights
Advertisement
Advertisement